

Ref. No: 0265
Date: 19/09/23
Subject: Treatment of Hidradenitis Suppurativa

REQUEST

I am trying to understand current practice in the treatment of Hidradenitis Suppurativa (HS). Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Bimekizumab
- Certolizumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Secukinumab
- Ustekinumab

RESPONSE

Please find information below, based on the inpatient diagnosis code of Hidradenitis Suppurativa from 01/06/2023 to 31/08/2023.

Treatment	No. Patients
Adalimumab - Humira	0
Adalimumab Biosimilar	<5
Bimekizumab	0
Certolizumab	0
Infliximab - Remicade	0
Infliximab Biosimilar	<5
Secukinumab	0
Ustekinumab	0

Section 40: personal information

We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances Section 40(2) and Section 40(3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection

principle which states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure, and in such circumstances, Section 40 confers an absolute exemption on disclosure.